• June 2022, Boston Scientific has been recognized with a Bronze Edison Award in the Science and Medical category for its Tria Ureteral Stent, the first stent made with a proprietary surface technology designed to provide protection against the accumulation of both urine calcium and magnesium salt deposits.

• May 2022, The United States Food and Drug Administration granted 510k clearance for a novel urinary stent developed by Dean Secrest and Lee Ponsky, MD, Chair of the Department of Urology and Leo and Charlotte Goldberg, Chair in Advanced Surgical Therapies at University Hospitals (UH) in Cleveland.

In this report, the Ureteral Stents Market has been segmented by Product, Raw Material, Application, End Users, and Geography.

Ureteral Stents Market, Segmentation by Product

The Ureteral Stents Market has been segmented by Product into Double Pigtail Stents, Open-End Stents, Closed-End Stents and Others.

Double Pigtail Stents

Double pigtail stents dominate the ureteral stents market, accounting for nearly 45% of the total share due to their enhanced anchorage and reduced migration risks. Their design allows secure placement in both the renal pelvis and bladder, making them ideal for long-term use.

Open-End Stents

Open-end stents hold a significant share of around 25%, valued for their ease of insertion and use in diagnostic procedures such as ureteral access or contrast studies. Their structure is suitable for short-term placement and temporary relief of obstruction.

Closed-End Stents

Closed-end stents comprise about 20% of the market and are primarily used when backflow prevention is critical. These stents are designed to minimize urinary reflux and irritation, especially in sensitive or postoperative patients.

Others

The ‘Others’ category, making up the remaining 10%, includes tailored stent designs and biodegradable variants. These are increasingly being adopted for personalized treatment plans and specific clinical scenarios where conventional stents may not be ideal.

Ureteral Stents Market, Segmentation by Raw Material

The Ureteral Stents Market has been segmented by Raw Material into Silicone, Polymer, Metal and Others.

Silicone

Silicone-based stents account for around 40% of the global market due to their biocompatibility, flexibility, and reduced encrustation risk. These stents are ideal for long-term implantation, offering high patient comfort and minimal tissue irritation.

Polymer

Polymer ureteral stents contribute nearly 35% of market share and are favored for their cost-effectiveness and ease of manufacturing. Commonly made from polyurethane or polyethylene, they offer moderate durability suitable for short- to mid-term applications.

Metal

Metal ureteral stents hold about 15% of the market, primarily used in cases of chronic obstruction or malignancy. These stents offer long-term patency and durability, though they are less flexible and more invasive than silicone or polymer alternatives.

Others

The ‘Others’ segment, contributing approximately 10%, includes hybrid materials and biodegradable compounds. These options are gaining traction in specialized procedures requiring customizable degradation rates and enhanced patient outcomes.

Ureteral Stents Market, Segmentation by Application

The Ureteral Stents Market has been segmented by Application into Ureteroscopy, Lithotripsy, Percutaneous Nephrolithotomy, Kidney Transplantation, Urinary Incontinence and Others.

Ureteroscopy

Ureteroscopy accounts for approximately 28% of the ureteral stents market, driven by its widespread use in stone management procedures. The stents help in maintaining ureteral patency post-procedure, minimizing the risk of post-operative obstruction or trauma.

Lithotripsy

This application segment holds nearly 22% share, where stents are used post-lithotripsy to ease the passage of stone fragments and reduce ureteral swelling. Their use ensures better patient outcomes and fewer complications during recovery.

Percutaneous Nephrolithotomy

Percutaneous nephrolithotomy contributes around 18% to the market, where stents assist in urine drainage and prevent blockages during healing. Their use is crucial in managing large or complex renal stones effectively.

Kidney Transplantation

Ureteral stents are utilized in nearly 15% of kidney transplant procedures to ensure unobstructed urine flow from the graft to the bladder. Their temporary placement significantly lowers the risk of urological complications post-transplant.

Urinary Incontinence

This segment represents about 10% of the application share, where stents aid in cases of neurogenic bladder dysfunction or obstructive uropathy. They help maintain bladder emptying and reduce infection risks.

Others

The remaining 7% includes diverse procedures like tumor management and reconstructive surgeries. In these cases, stents provide temporary support to the urinary tract, improving patient safety and treatment efficiency.

Ureteral Stents Market, Segmentation by End Users

The Ureteral Stents Market has been segmented by End Users into Hospitals, Clinics and Ambulatory Surgical Centers.

Hospitals

Hospitals dominate the end-user segment with a market share of approximately 58%, owing to their capacity to perform complex urological procedures and manage post-operative care. They are equipped with advanced diagnostic and surgical infrastructure, making them the primary setting for ureteral stent usage.

Clinics

Clinics hold around 25% of the market, playing a crucial role in follow-up care, stent monitoring, and less-invasive outpatient treatments. They offer a more accessible and cost-effective option for routine stent management and minor interventions.

Ambulatory Surgical Centers

Ambulatory Surgical Centers contribute nearly 17% to the market, primarily driven by the increasing preference for day-care surgical procedures. These centers are equipped to handle minimally invasive urological surgeries, providing faster discharge and lower healthcare costs.

Ureteral Stents Market, Segmentation by Geography

In this report, the Ureteral Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Ureteral Stents Market Share (%), by Geographical Region, 2024

North America

North America accounts for the largest share of the ureteral stents market, representing around 38% of the global revenue. The region benefits from a well-established healthcare infrastructure, rising incidences of kidney disorders, and favorable reimbursement policies, particularly in the U.S.

Europe

Europe holds approximately 27% of the market, driven by a strong presence of specialized healthcare facilities and high awareness of urological conditions. Countries such as Germany, France, and the UK are leading contributors, emphasizing minimally invasive urological procedures.

Asia Pacific

Asia Pacific is witnessing the fastest growth and currently captures nearly 20% of the market. Rapidly expanding healthcare access, rising urolithiasis cases, and increased government investments in healthcare infrastructure are fueling demand, especially in China and India.

Middle East and Africa

Middle East and Africa collectively contribute about 9% to the global market. Although still emerging, countries like the UAE and South Africa are improving access to advanced urological diagnostics and surgical care, driving gradual market expansion.

Latin America

Latin America accounts for around 6% of the ureteral stents market. Growth is supported by an increase in urology-focused programs and better public-private healthcare partnerships in countries such as Brazil, Mexico, and Argentina.

This report provides an in depth analysis of various factors that impact the dynamics of Global Ureteral Stents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Rising prevalence of kidney stones and urological disorders
• Growing geriatric population with higher risk of urinary complications
• Increasing adoption of minimally invasive urological procedures

• Technological advancements in stent materials and designs - Technological advancements in stent materials and designs are significantly driving growth in the ureteral stents market. Innovations such as biodegradable stents, anti-microbial coatings, and more flexible, patient-friendly materials have improved stent performance, reduced complications, and enhanced patient comfort. These developments address long-standing issues like infection, encrustation, and discomfort, making next-generation ureteral stents more effective and reliable for both short-term and long-term applications.
  
  Enhanced designs that offer better drainage, easier insertion, and compatibility with minimally invasive procedures are also gaining popularity among urologists. As healthcare providers increasingly seek advanced and patient-centric urological solutions, the demand for technologically superior stents continues to rise. This trend not only improves clinical outcomes but also supports the broader adoption of ureteral stents in managing various urinary tract disorders.

Restraints

• Complications associated with stents
• Stringent regulatory requirements
• High cost of procedures

• Limited reimbursement policies - Limited reimbursement policies act as a significant restraint on the growth of the ureteral stents market. In many regions, healthcare systems offer only partial or no coverage for stent placement procedures, making treatment costly for both providers and patients. This financial burden can lead to delays in necessary interventions or a preference for less effective alternatives, ultimately impacting patient outcomes and stent adoption rates.

  The lack of comprehensive reimbursement particularly affects the use of advanced or premium stent technologies, which tend to be more expensive. Hospitals and clinics may hesitate to adopt these innovations due to uncertain returns on investment. Without adequate policy support, the full potential of technological advancements in ureteral stents remains underutilized, limiting market growth in both developed and developing healthcare settings.

Opportunities

• Innovative product developments
• Minimally invasive techniques

• Strategic collaborations and partnerships: The ureteral stents market has witnessed significant growth in recent years, driven by strategic collaborations and partnerships among key players in the industry. These collaborations aim to leverage each company's strengths and resources to enhance product development, expand market reach, and improve patient outcomes. Through partnerships, companies can combine their expertise in medical device technology, research and development, and marketing to bring innovative solutions to the market more efficiently.

  One prominent trend in the ureteral stents market is collaborations between medical device manufacturers and healthcare providers. By working closely with urologists, hospitals, and clinics, manufacturers gain valuable insights into the evolving needs of patients and clinicians. This collaboration often leads to the development of stents that are more tailored to specific clinical scenarios, improving patient comfort and reducing complications. Additionally, partnerships with healthcare providers can facilitate clinical trials and real-world evidence generation, supporting regulatory approvals and reimbursement decisions.

Key players in Global Ureteral Stents Market include:

• Boston Scientific Corporation
• Cook Medical Inc
• C. R. Bard, Inc
• Coloplast Corp
• Teleflex Incorporated
• Medtronic plc
• Olympus Corporation
• Allium Medical Solutions Ltd
• Pnn Medical A/S
• Applied Medical Resources Corporation

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis